Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION

Buy cheap v i a g r a online to cure impotence.

         

 

Using some of the most powerful nuclear magnetic resonance equipment available, researchers at the University of California, Davis, are making discoveries about the shape and structure of biological molecules - potentially leading to new ways to treat or prevent diseases such as breast cancer and Alzheimer’s disease…

 

A Queensland University of Technology (QUT) PhD student has developed a potential breakthrough test for predicting the likelihood of the spread or return of breast cancer…

 

The presence of circulating tumor cells in the blood appears to have no relationship to survival in women who have just been diagnosed with inflammatory breast cancer, according to new research from Fox Chase Cancer Center. However, the research shows that these stray tumor cells may signal that the disease has spread to other parts of the body, even before imaging reveals any metastases…

 

Collaboration between research, hospital and industry aimed at transferring innovative procedure into daily practice. The Paul Scherrer Institute (PSI) has developed a new breast cancer diagnostic method, and is now carrying out first tests on non-preserved human tissue in conjunction with the Kantonsspital Baden AG…

 

In Screening for Breast Cancer, One Guideline Not Appropriate for All Women Mammography Screening Increments Should be Based on Individual Risk Factors Experts disagree on the optimal screening intervals for mammography…

 

A study spearheaded by the University of Leicester aims to find out whether a blood test can detect cancer, earlier than current methods, in women with a strong family history of breast cancer. Leicestershire cancer research charity Hope Against Cancer is supporting the study with a £90,000 Maria Tilton Research Fellowship based at the University of Leicester…

 

A study revealed at SNM’s 58th Annual Meeting is comparing the breast-tumor detection capabilities of two very different imaging technologies - breast-specific gamma imaging (BSGI), which provides functional images of breast physiology, and ultrasound - for women with complex breast imaging cases that require further evaluation…

 

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages. The MAMMI (MAMmography with Molecular Imaging) device will allow doctors to start treatments one or even two years earlier than usual and also evaluate the patient’s response to chemotherapy…

 

Dune Medical Devices, Inc. has announced that the landmark, 664-patient pivotal trial evaluating the MarginProbe™ System met its primary endpoints. The MarginProbe System provides surgeons with a real time, intraoperative technology to detect microscopically-positive margins on excised tissues…

 

Genomic Health, Inc. (Nasdaq: GHDX) announced the launch of RxPONDER S1007 (Rx for Positive Node, Endocrine Responsive Breast Cancer), a clinical trial being led by SWOG, one of the largest National Cancer Institute (NCI) supported cancer cooperative groups…




February 2012
Mon Tue Wed Thu Fri Sat Sun
« Jan    
 12345
6789101112
13141516171819
20212223242526
272829